- Anaphylaxis following H1N1 pandemic vaccines: safety data in perspectiveFernanda Tavares
GlaxoSmithKline Biologicals, Wavre, Belgium
Vaccine 29:6402-7. 2011..Our analysis also highlighted the challenges of reliably determining the rate of anaphylaxis as an adverse event in the postmarketing setting following mass vaccination, as anaphylaxis was excluded in 45.8% of reported cases...
- Pregnancy and safety outcomes in women vaccinated with an AS03-adjuvanted split virion H1N1 (2009) pandemic influenza vaccine during pregnancy: a prospective cohort studyFernanda Tavares
Global Vaccine Development, GlaxoSmithKline GSK Biologicals, Parc de la Noire Epine, Avenue Fleming 20, 1300 Wavre, Belgium
Vaccine 29:6358-65. 2011....
- The safety evaluation of adjuvants during vaccine development: the AS04 experienceNathalie Garçon
GlaxoSmithKline Biologicals, Avenue Fleming, 20, 1300 Wavre, Belgium
Vaccine 29:4453-9. 2011..We also discuss how the knowledge of adjuvant mode of action can support the current practice of safety evaluation...